Malignant peritoneal mesothelioma (MPeM) is a rare and aggressive cancer of the abdominal lining. A recent multi-center study has shed light on the effectiveness of various treatments for this condition. The study divided patients into two groups: those who underwent cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and those who could not undergo curative surgery.
The CRS-HIPEC group showed significantly better outcomes, with a median overall survival (OS) of 44.6 months compared to 12.6 months for non-surgical treatments. This combination therapy is particularly beneficial for patients who can achieve complete or near-complete tumor resection. Factors such as low completeness of cytoreduction (CC) scores and low peritoneal cancer index (PCI) scores were associated with better survival rates.
For patients who are not surgical candidates, chemotherapy remains the primary treatment option. The platinum-pemetrexed regimen is particularly effective, with patients showing improved progression-free survival (PFS) and OS compared to other treatments.
The study underscores the importance of personalized treatment plans based on the patient’s specific condition and prognosis. It also highlights the role of experienced surgical centers in achieving optimal outcomes. Continuous advancements in surgical techniques and chemotherapy regimens are improving survival rates for MPeM patients.
For detailed information, read the full study here.
https://link.springer.com/article/10.1245/s10434-024-15506-3
Leave a Reply